携带抗血管生成药物栓塞剂的研究进展  

Progress in embolic agents carry anti-angiogenesis drugs

作　　者：游箭[1] 杨巧丽[2] 林洋[2] 何学红[1] 李蓉芬[1] 

机构地区：[1]川北医学院第二临床医学院.南充市中心医院影像科/介入放射科,四川南充637000 [2]泸州医学院附属医院放射科,四川泸州646000

出　　处：《西部医学》2016年第4期445-447,共3页Medical Journal of West China

基　　金：四川省教育厅重点项目(11ZA188);南充市科技支撑项目(11A0118)

摘　　要：经导管血管栓塞术是肿瘤介入治疗的重要技术,通过将栓塞剂有控制性的注入肿瘤血管内,使血管闭塞,发挥阻断血供、治疗肿瘤的作用。但介入栓塞后肿瘤内部缺血缺氧,常诱导新生血管形成,间接促进肿瘤复发、转移。因此,抗血管生成药物具有重要作用。随着研究的进展,携带抗血管生成药物的栓塞剂因其可发挥栓塞、抗血管生成的双重作用逐渐成为研究热点,本文就其研究进展作一述评。Transcatheter embolization is an important technology of tumor interventional therapy,by controlling embolic agents injected into the tumor blood vessels,blocking blood vessels and blood supply to play a therapeutic role in cancer.But the tumor will be ischemia and hypoxia after embolization,which often induce angiogenesis indirectly and promote tumor recurrence and metastasis.Thus,anti-angiogenic drugs have an important role.With the progress of the study,carried anti-angiogenic drugs embolization embolic agents become a hot topic,because its dual role of embolic and anti-angiogenic gradually.

关 键 词：血管生成 介入 栓塞剂 

分 类 号：R730.55[医药卫生—肿瘤]